Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunctionwithout affecting blood pressure in angiotensin II-high salt-induced hypertension

Journal of Hypertension

Volumn 33, Issue 1, 2015, Pages 144-152

  González, Germán E ^a,b   Rhaleb, Nour Eddine ^a,c   D'Ambrosio, Martin A ^a   Nakagawa, Pablo ^a   Liu, Yunhe ^a   Leung, Pablo ^a   Dai, Xiangguo ^a   Yang, Xiao Ping ^a,d   Peterson, Edward L ^a   Carretero, Oscar A ^a  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c Department of Physiology ^*  (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Heart failure; Hypertension; Interleukin 6

Indexed keywords

ALBUMINOID; ANGIOTENSIN II; INTERLEUKIN 6; SALT INTAKE;

ADVERSE EFFECTS; ANIMAL; BLOOD PRESSURE; C57BL MOUSE; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CARDIOMEGALY; CHEMISTRY; COMPLICATION; DRUG EFFECTS; ECHOCARDIOGRAPHY; FIBROSIS; GENETICS; HEART; HEART RATE; HYPERTENSION; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; MALE; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; SALT INTAKE;

ALBUMINS; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; ECHOCARDIOGRAPHY; FIBROSIS; HEART; HEART RATE; HYPERTENSION; INFLAMMATION; INTERLEUKIN-6; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; MYOCYTES, CARDIAC; PHENOTYPE; SODIUM CHLORIDE, DIETARY;

EID: 84916897951     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000358     Document Type: Article

References (40)

1. Harrison DG, Marvar PJ, Titze JM. Vascular inflammatory cells in hypertension. Front Physiol 2012; 3: 128.
2. Peng H, Yang XP, Carretero OA, Nakagawa P, D'Ambrosio M, Leung P, et al. Angiotensin II-induced dilated cardiomyopathy in Balb/c but not C57BL/6J mice. Exp Physiol 2011; 96: 756-764.
3. Yu Q, Vazquez R, Zabadi S, Watson RR, Larson DF. T-lymphocytes mediate left ventricular fibrillar collagen cross-linking and diastolic dysfunction in mice. Matrix Biol 2010; 29: 511-518.
4. Abbas AK, Lichtman AHH, Pillai S. Cellular and molecular immunology. Philadelphia, PA: Elsevier Health Sciences; 1994.
5. Luther JM, Gainer JV, Murphey LJ, Yu C, Vaughan DE, Morrow JD, et al. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 2006; 48: 1050-1057.
6. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38: 399-403.
7. Coles B, Fielding CA, Rose-John S, Scheller J, Jones SA, O'Donnell VB. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am J Pathol 2007; 171: 315-325.
8. Lee DL, Sturgis LC, Labazi H, Osborne JB Jr, Fleming C, Pollock JS, et al. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol 2006; 290: H935-H940.
9. Zhang W, Wang W, Yu H, Zhang Y, Dai Y, Ning C, et al. Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension 2012; 59: 136-144.
10. Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010; 56: 225-231.
11. Boesen EI, Pollock DM. Effect of chronic IL-6 infusion on acute pressor responses to vasoconstrictors in mice. Am J Physiol Heart Circ Physiol 2007; 293: H1745-H1749.
12. Banerjee I, Fuseler JW, Intwala AR, Baudino TA. IL-6 loss causes ventricular dysfunction, fibrosis, reduced capillary density, and dramatically alters the cell populations of the developing and adult heart. Am J Physiol Heart Circ Physiol 2009; 296: H1694-H1704.
13. Rhaleb N-E, Yang XP, Nanba M, Shesely EG, Carretero OA. Effect of chronic blockade of the Kallikrein-Kinin system on the development of hypertension in rats. Hypertension 2001; 37: 121-128.
14. Yang XP, Liu YH, Rhaleb N-E, Kurihara N, Kim HE, Carretero OA. Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am J Physiol Heart Circ Physiol 1999; 277 (5 Pt 2): H1967-H1974.
15. Cavallero S, Gonzalez GE, Seropian IM, Cerrudo CS, Matorra F, Morales C, et al. Ventricular function and natriuretic peptides in sequentially combined models of hypertension. Am J Physiol Heart Circ Physiol 2010; 298: H1290-H1299.
16. Gonzalez GE, Seropian IM, Krieger ML, Palleiro J, Lopez Verrilli MA, Gironacci MM, et al. Effect of early versus late AT(1) receptor blockade with losartan on postmyocardial infarction ventricular remodeling in rabbits. Am J Physiol Heart Circ Physiol 2009; 297: H375-H386.
17. Liu Y-H, Xu J, Yang X-P, Yang F, Shesely E, Carretero OA. Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure. Hypertension 2002; 39 (2 Pt 2): 375-381.
18. Rhaleb N-E, Pokharel S, Sharma U, Carretero OA. Renal protective effects of N-Acetyl-Ser-Asp-Lys-Pro in deoxycorticosterone acetate-salt hypertensive mice. J Hypertens 2011; 29: 330-338.
19. Monassier L, Combe R, Fertak LE. Mouse models of hypertension. Drug Discov Today: Dis Models 2006; 3: 273-281.
20. Breckenridge R. Heart failure and mouse models. Dis Model Mech 2010; 3: 138-143.
21. Patten RD, Hall-Porter MR. Small animal models of heart failure: Development of novel therapies, past and present. Circ Heart Fail 2009; 2: 138-144.
22. Muirhead EE, Leach BE, Armstrong FB. Angiotensin-salt hypertension. Clin Sci Mol Med Suppl 1973; 45 (Suppl 1): 257s-261s.
23. Enzler T, Bonizzi G, Silverman GJ, Otero DC, Widhopf GF, nzelon-Mills A, et al. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 2006; 25: 403-415.
24. Brands MW, Banes-Berceli AK, Inscho EW, Al-Azawi H, Allen AJ, Labazi H. Interleukin 6 knockout prevents angiotensin II hypertension: Role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation. Hypertension 2010; 56: 879-884.
25. Schrader LI, Kinzenbaw DA, Johnson AW, Faraci FM, Didion SP. IL-6 deficiency protects against angiotensin II-induced endothelial dysfunction and hypertrophy. Arterioscler Thromb Vasc Biol 2007; 27: 2576-2581.
26. Fisman EZ, Benderly M, Esper RJ, Behar S, Boyko V, Adler Y, et al. Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol 2006; 98: 14-18.
27. Hirota H, Izumi M, Hamaguchi T, Sugiyama S, Murakami E, Kunisada K, et al. Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. Heart Vessels 2004; 19: 237-241.
28. Ohtsuka T, Hamada M, Inoue K, Ohshima K, Sujzuki J, Matsunaka T, et al. Relation of circulating interleukin-6 to left ventricular remodeling in patients with reperfused anterior myocardial infarction. Clin Cardiol 2004; 27: 417-420.
29. Yan AT, Yan RT, Cushman M, Redheuil A, Tracy RP, Arnett DK, et al. Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: Insights from the Multi-Ethnic Study of Atherosclerosis. Eur Heart J 2010; 31: 875-882.
30. Lai NC, Gao MH, Tang E, Tang R, Guo T, Dalton ND, et al. Pressure overload-induced cardiac remodeling and dysfunction in the absence of interleukin 6 in mice. Lab Invest 2012; 92: 1518-1526.
31. Levick SP, Murray DB, Janicki JS, Brower GL. Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart. Hypertension 2010; 55: 270-276.
32. Liao TD, Yang XP, D'Ambrosio M, Zhang Y, Rhaleb N-E, Carretero OA. N-Acetyl-seryl-Aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: Council for High Blood Pressure Research. Hypertension 2010; 55: 459-467.
33. Ma F, Li Y, Jia L, Han Y, Cheng J, Li H, et al. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF beta/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One 2012; 7: E35144.
34. Xu J, Carretero OA, Liao TD, Peng H, Shesely EG, Xu J, et al. Local angiotensin II aggravates cardiac remodeling in hypertension. Am J Physiol Heart Circ Physiol 2010; 299: H1328-H1338.
35. Kobara M, Noda K, Kitamura M, Okamoto A, Shiraishi T, Toba H, et al. Antibody against interleukin-6 receptor attenuates left ventricular remodelling after myocardial infarction in mice. Cardiovasc Res 2010; 87: 424-430.
36. Janssen SP, Gayan-Ramirez G, Van den BA, Herijgers P, Maes K, Verbeken E, et al. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation 2005; 111: 996-1005.
37. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238.
38. Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 2010; 55: 500-507.
39. Kvakan H, Kleinewietfeld M, Qadri F, Park JK, Fischer R, Schwarz I, et al. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation 2009; 119: 2904-2912.
40. Seropian IM, Toldo S, Van Tassell BW, Abbate A. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J Am Coll Cardiol 2014; 63: 1593-1603.